# mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

> **NCT02208375** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 159 (actual)

## Conditions studied

- BRCA1 Mutation Carrier
- BRCA2 Mutation Carrier
- Endometrial Adenocarcinoma
- Estrogen Receptor Negative
- HER2/Neu Negative
- High Grade Ovarian Serous Adenocarcinoma
- Progesterone Receptor Negative
- Recurrent Breast Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Uterine Corpus Carcinoma
- Stage III Uterine Corpus Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7
- Stage IV Uterine Corpus Cancer AJCC v7
- Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Capivasertib
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Olaparib
- **OTHER:** Pharmacological Study
- **DRUG:** Vistusertib

## Key facts

- **NCT ID:** NCT02208375
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-11-11
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2025-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02208375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02208375, "mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02208375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*